Bailey Mark J, Dickinson Ronald G
Department of Medicine, Centre for Studies in Drug Disposition, The University of Queensland at Royal Brisbane Hospital, Queensland 4029, Australia.
Chem Biol Interact. 2003 May 6;145(2):117-37. doi: 10.1016/s0009-2797(03)00020-6.
The metabolic conjugation of exogenous and endogenous carboxylic acid substrates with endogenous glucuronic acid, mediated by the uridine diphosphoglucuronosyl transferase (UGT) superfamily of enzymes, leads to the formation of acyl glucuronide metabolites. Since the late 1970s, acyl glucuronides have been increasingly identified as reactive electrophilic metabolites, capable of undergoing three reactions: intramolecular rearrangement, hydrolysis, and intermolecular reactions with proteins leading to covalent drug-protein adducts. This essential dogma has been accepted for over a decade. The key question proposed by researchers, and now the pharmaceutical industry, is: does or can the covalent modification of endogenous proteins, mediated by reactive acyl glucuronide metabolites, lead to adverse drug reactions, perhaps idiosyncratic in nature? This review evaluates the evidence for acyl glucuronide-derived perturbation of homeostasis, particularly that which might result from the covalent modification of endogenous proteins and other macromolecules. Because of the availability of acyl glucuronides for test tube/in vitro experiments, there is now a substantial literature documenting their rearrangement, hydrolysis and covalent modification of proteins in vitro. It is certain from in vitro experiments that serum albumin, dipeptidyl peptidase IV, tubulin and UGTs are covalently modified by acyl glucuronides. However, these in vitro experiments have been specifically designed to amplify any interference with a biological process in order to find biological effects. The in vivo situation is not at all clear. Certainly it must be concluded that all humans taking carboxylate drugs that form reactive acyl glucuronides will form covalent drug-protein adducts, and it must also be concluded that this in itself is normally benign. However, there is enough in vivo evidence implicating acyl glucuronides, which, when backed up by in vivo circumstantial and documented in vitro evidence, supports the view that reactive acyl glucuronides may initiate toxicity/immune responses. In summary, though acyl glucuronide-derived covalent modification of endogenous macromolecules is well-defined, the work ahead needs to provide detailed links between such modification and its possible biological consequences.
由尿苷二磷酸葡萄糖醛酸基转移酶(UGT)超家族酶介导的外源性和内源性羧酸底物与内源性葡萄糖醛酸的代谢结合,会导致酰基葡萄糖醛酸代谢物的形成。自20世纪70年代末以来,酰基葡萄糖醛酸越来越多地被鉴定为具有反应活性的亲电代谢物,能够发生三种反应:分子内重排、水解以及与蛋白质的分子间反应,从而导致共价药物 - 蛋白质加合物的形成。这一基本理论已被接受了十多年。研究人员以及现在的制药行业提出的关键问题是:由反应性酰基葡萄糖醛酸代谢物介导的内源性蛋白质的共价修饰是否或能否导致药物不良反应,或许本质上是特异质性的?这篇综述评估了酰基葡萄糖醛酸引起体内稳态紊乱的证据,特别是那些可能由内源性蛋白质和其他大分子的共价修饰导致的证据。由于可获得用于试管/体外实验的酰基葡萄糖醛酸,现在有大量文献记录了它们在体外对蛋白质的重排、水解和共价修饰。从体外实验可以确定,血清白蛋白、二肽基肽酶IV、微管蛋白和UGT会被酰基葡萄糖醛酸共价修饰。然而,这些体外实验是专门设计用来放大对生物过程的任何干扰,以便发现生物学效应的。体内情况则完全不清楚。当然,可以得出结论,所有服用形成反应性酰基葡萄糖醛酸的羧酸盐药物的人都会形成共价药物 - 蛋白质加合物,而且也必须得出结论,这本身通常是无害的。然而,有足够的体内证据涉及酰基葡萄糖醛酸,当得到体内间接证据和记录在案的体外证据支持时,这支持了反应性酰基葡萄糖醛酸可能引发毒性/免疫反应的观点。总之,虽然酰基葡萄糖醛酸对内源性大分子的共价修饰已得到明确界定,但未来的工作需要提供这种修饰与其可能的生物学后果之间的详细联系。